0 citations
Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel
Frontiers in Oncology2023Vol. 13, pp. 1257404–1257404
Citations Over Time
Mingyue Xia, Shuyan Wang, Yannan Qi, Kaili Long, Enjie Li, Lingfeng He, Feiyan Pan, Zhigang Guo, Zhigang Hu
Abstract
[This corrects the article DOI: 10.3389/fonc.2022.993243.].
Related Papers
- → No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer(2017)14 cited
- → Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer(2012)19 cited
- → Chemotherapy for androgen-independent prostate cancer(2005)23 cited
- → Docetaxel-Based Therapy for Prostate Cancer(2005)
- → Pros and cons of docetaxel used to treat metastatic hormone-sensitive prostate cancer: The cons(2016)